Vismodegib and Sonidegib Are Associated With an Elevated Reporting Odds of Squamous Cell Carcinoma; a Comparative Pharmacovigilance Study of the FDA Adverse Events Reporting System (FAERS).

BACKGROUND: Direct comparison of the adverse effect (AE) profiles of the hedgehog inhibitor (HIs) medications is limited to post hoc analyses of phase III clinical trials. OBJECTIVE: Compare the AE profiles between vismodegib and sonidegib in the FDA…

Preview only. Read the full abstract at the source